A combination study of 3 and 6 in participants with PARP-resistant recurrent ovarian cancer,to assess the safety of the combination, the response rate, and thepercentage of participants who proceed to 6 months progression-freesurvival among patients who have developed PARPi resistance and toassess the indicators of response and progression of this diseasefollowing the combination therapy. Here, PARP1 is linked to ovarian cancer.